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1. INTRODUCTION 
The difficulty of reducing ischaemia-reperfusion (I/R) injury and 
hypoxia is a major problem in cardiology and cardiovascular surgery, 
and is also related to problems that occur during organ 
transplantation. The aim of cardioprotection during and after I/R 
injury in a clinical setting is to reduce the infarct size, prevent severe 
cardiac arrhythmias and increase the contractile function of the intact 
myocardium. Cardiovascular protection during decreased blood and 
oxygen supply is extensively discussed and studied in 
pathophysiology and clinical research. Therapeutic strategies have 
improved over recent years; at present, drug research and operative 
developments have resulted in better outcomes and prognoses even 
for patients with complicated disorders. However, the development 
and investigation of new cardioprotective drugs is necessary because 
cardiovascular ischaemia-related disorders are some of the leading 
causes of death in the developed world. This thesis therefore focuses 
on cardiac and vascular protection against I/R injury. It attempts to 
identify potential targets for novel therapeutic options to reduce 
ischaemia- and reperfusion-related organ damage, function loss of 
implanted organs and mortality.  
1.1. Hypoxic adaptation mechanisms  
Mammals have oxygen sensing mechanisms that help cells adapt to 
hypoxia. In the course of evolution, some cell groups specialised to 
sense O2 tension, including the carotid body, pulmonary artery, 
adrenal chromaffin cells, mitochondria via reactive oxygen species, 
energy state and cytosolic redox state. Hypoxia-inducible factor 
(HIF)-1 is a heterodimeric transcription factor consisting of the 
consecutively expressed HIF-β (also called ARNT) and a regulatory 
HIF-α subunit (mainly post-translationally regulated), which 
regulates after dimerisation. The regulation of HIF-1α is regulated 
via prolil hydroxlases (PHD). Under normoxic condition PHD leads 
to degradation of HIF-1α, in contrast under hypoxic conditions HIF-
1α can be expressed and translocate into the nucleus, were they bind 
to hypoxia responsible element and induce expression of several 
adaptive genes. The HIF-1α in animal infarct models improved 
myocardial perfusion, maintained ventricular function and cardiac 
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HIF-1α overexpression which reduced the myocardial infarct size 
and promoted post-ischaemic function and capillarisation. This 
suggests that HIF-1α activation/stabilisation is beneficial in cardiac 
ischaemic syndromes. The mechanism of how HIF activation can 
protect cells against I/R injury has not been completely explored, 
although it involves several pathways such as antioxidant, 
angiogenesis, cell death and antiapoptotic pathways. Drugs, such as 
dimethyloxalilglycin (DMOG), which can induce HIF stabilisation 
under normoxic conditions, could be one of the next generation 
treatments for myocardial infarction, stroke, renal or liver injury, 
peripheral vascular disease or severe anaemia. In this study, we 
investigated the potential beneficial effects of treatment with DMOG 
in the model of vascular ischemic injury.  
1.2. Role of zinc in cytoprotection during I/R injury 
Disruption of zinc homeostasis is associated with severe 
pathophysiological conditions such as decreased erythrocyte copper–
zinc superoxide dismutase, increased low-density lipoprotein 
cholesterol, decreased high-density lipoprotein cholesterol, decreased 
methionine and leucine encephalins, decreased glucose clearance and 
abnormal cardiac function. However it leads to oxidative stress, 
which is the main and common point in the pathophysological 
processes.  Copper- or iron-binding sites of macromolecules such as 
DNA, peptides or proteins, nucleotides or glucose behave as centres 
for production of hydroxyl radicals via Fenton reaction. The acute 
protective role of zinc ions for myocardial tissue is mainly due to 
changes in redox homeostasis: a decrease in generation of 
.
OH from 
H2O2 due to antagonism of redox-active metals such as iron and 
copper. The other mechanism is the stabilisation of sulfhydryl, where 
zinc protects several enzymes (e.g. delta-aminolevulinate 
dehydratase, dihydroorotase and tubulin). Numerous publications 
over the last 10–20 years have reported on the protective effects of 
zinc. Several authors have also published data on different zinc 
complexes such as chloride salt or zinc complexed with carnosine, 
histidinate or aspartate. The fact remains that the one common 
component of all of these studies is the presence of zinc. In this 
study, we investigated the potential beneficial effects of Q50, an 
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iron-chelating and zinc-complexing agent that belongs to the 8-
hydroxyquinoline family. Therefore, Q50 may be a good candidate 
as a therapeutic agent because of its iron-chelating potential. In 
addition, it acts on intracellular sources of zinc, forming a protective 
complex.  
2. OBJECTIVES 
The objectives of this study were to describe the pathophysiological 
changes to the vascular system and myocardium during and after I/R 
injury using rodent models. The use of antioxidants and effect of the 
HIF stabilisation under myocardial or vascular ischaemic conditions 
were investigated. This may help to improve our understanding of 
the role of these pathways and form the basis for future 
developments. 
The first aim of this study was to focus on the role of the HIF in 
vascular cold ischaemic storage and warm reperfusion injury. We 
treated isolated rat aortic rings with DMOG (due to PHD inhibition 
induced HIF stabilisation) and simulated reperfusion injury in an 
organ bath by adding hypochlorite. In addition to the vascular 
functional measurements, we investigated the cellular and molecular 
changes. 
 
The second aim of this study was to investigate the activity and 
characteristics of the newly developed iron-chelating and zinc-
complexing agent Q50. This study was carried out in rodent models 
of regional and global myocardial I/R. Regional myocardial 
ischaemia was induced in the rodent model by ligation of the left 
anterior descending (LAD) coronary artery. Global myocardial 
ischaemia was induced by orthotopic heart transplantation. Cellular 
and molecular changes to the heart were investigated after cardiac 
functional measurements were performed. 
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3. METHODS 
 
3.1. Effects of prolyl hydroxylase inhibition on vascular 
function 
3.1.1. Animals 
Sprague Dawley rats (male, 250–350 g) were used in the 
experiments. The rats were randomly assigned to different groups. 
3.1.2. Experimental groups 
The aortic segments for the organ bath experiments were randomised 
into three groups: 1) control group, the aortic rings were 
immediately mounted in the organ bath; 2) Sodium hypochlorite 
(NaOCl) group, the aortic rings were preserved in saline at 4°C for 
24 h after explantation; 3) DMOG group, the aortic rings were stored 
at 4°C for 24 h in saline or in 10−4 M DMOG-supplemented saline. 
Vascular smooth muscle cells (VSMC) were divided into three 
groups: 1) control group, without cold ischaemia and warm 
reperfusion; 2) NaCl group, cells were stored at 4°C in saline for 24 
h followed by 6 h warm reperfusion in a normal medium at 37°C; 3) 
DMOG (10
−3
M) group, cells were stored at 4°C in DMOG-
supplemented saline for 24 h followed by 6 h warm reperfusion in a 
normal medium at 37°C. 
3.1.3. Model of in vitro cold ischaemic storage and warm 
reperfusion-induced vascular injury 
After 24 h of cold storage, we investigated in vitro vascular functions 
in an organ bath. Therefore, the aortic rings were investigated in a 
similar manner, with additional exposure to NaOCl for 30 min and 
rinsed before phenylephrine pre-contraction. The different 
preservation solutions were aerated with nitrous oxide to reduce the 
oxygen concentration, simulating hypoxic conditions. 
3.1.3.1. Preparation and in vitro assessment of aortic rings 
vascular function 
Rats were anaesthetised with an intraperitoneal pentobarbital 
injection. After a bilateral thoracotomy, the thoracic aorta was 
removed and immediately placed in a cold Krebs–Henseleit solution 
(KHS). After dissecting the fat and connective tissue, 4 mm length 
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segments of the aorta were placed in test tubes with different 
solutions. Isolated aortic rings were mounted on stainless steel hooks 
in individual organ baths containing 25 ml of KHS at 37°C. The 
aortic rings were placed under a resting tension of 2 g and 
equilibrated for 60 min. At the beginning of each experiment, 
maximal contraction forces in response to KCl were determined, and 
the aortic rings were washed until the resting tension was obtained 
again. Aortic preparations were pre-constricted with phenylephrine 
(10
−6
 M), the α-adrenergic receptor agonist, until a stable plateau was 
obtained. Relaxation responses were examined by adding cumulative 
concentrations of endothelium-dependent dilator acetylcholine (10
−9–
10
−4
 M). To test the relaxation responses of VSMC, a direct nitric 
oxide-donor, sodium nitroprusside (SNP, 10
−10−10−5 M), was used. 
Contractile responses to phenylephrine are expressed as a percentage 
of the maximal contraction induced by KCl. Vasorelaxation and its 
maximum (Rmax) were expressed as a percentage of the contraction 
induced by phenylephrine.  
3.1.4. Cold ischaemic storage and warm reperfusion injury on 
VSMC 
VSMC were isolated from rat aortas, re-suspended in a base medium, 
plated and incubated in 6-well plates. The medium was changed for a 
saline or DMOG-supplemented saline solution, incubated for 24 h 
and stored for hypothermic ischaemia at 4°C. After the cold storage, 
the complete cell culture medium was added, and reperfusion was 
simulated by further incubation at 37°C for 6 h. 
3.1.5. Aortic and VSMC mRNA expression by quantitative real-
time polymerase chain reaction 
The expression of HO-1 in aortic rings and VSMC was determined. 
mRNA was isolated from aortic rings after 0, 2, 4 and 6 h of warm 
reperfusion. Sample quantifications were normalised to a 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression 
using a pool of all cDNAs from the control group.  
3.1.6. Statistical analyses 
Statistical analyses were performed using Origin v. 7.0 (OriginLab 
Corporation). Data distribution was tested for normality using the 
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Shapiro–Wilk test. Normally distributed data are expressed as mean 
± standard error of the mean (SEM). Two groups were compared 
using Student’s t-test and more than two groups (e.g. PCR, 
immunohistochemical scores and VSMC assay) were compared 
using one-way analysis of variance (ANOVA) with Bonferroni 
correction for multiple post hoc comparisons. P < 0.05 was 
considered to be statistically significant. 
 
3.2. Q50 in the I/R rat models 
3.2.1. Rat model of myocardial I/R injury: surgical preparation 
of regional I/R 
Rats were anaesthetised with sodium pentobarbital. An intratracheal 
tube was inserted to artificially ventilate the animals. The chest was 
opened via a left thoracotomy followed by a pericardiotomy. A 
single silk suture was passed around the LAD coronary artery, and 
the ends were pulled through a small pledget to form a snare and 
then tightened. After 45 min of ischaemia, reperfusion was achieved 
by releasing the snare. Sham-operated animals were subjected to the 
same surgical procedures, except that the suture around the LAD 
coronary artery was not tied. 
3.2.1.1. Experimental groups 
The rats were randomised into four groups: 1) Sham rats received the 
vehicle but no tightening of the coronary suture; 2) Sham + Q50 rats 
received Q50 and the ligature was placed around the LAD but 
without occlusion; 3) I/R rats were treated with the vehicle and 
subjected to I/R; 4) I/R + Q50 rats were given Q50 and subjected to 
I/R, undergoing 45 min of myocardial ischaemia, followed by 24 h 
of reperfusion. Vehicle or Q50 were given as an intravenous bolus 5 
min before the onset of reperfusion. 
3.2.1.2. In vivo haemodynamic parameters 
After 24 h of reperfusion, the rats were anaesthetised with sodium 
pentobarbital, tracheotomised, intubated and artificially ventilated. 
To assess cardiac function, a left ventricular (LV) pressure-volume 
analysis was performed with a pressure-volume catheter. 
 
8 
 
3.2.2. Rat model of global myocardial ischemia: heterotopic 
heart transplantation 
Transplantations were performed in an isogenic Lewis to Lewis rat 
strain. In brief, the donor rats were intraperitoneally anesthetised 
with a mixture of ketamine and xylazine and then heparinised. 
Cardiac arrest was induced by administering a Custodiol
®
 solution. 
After 1 h of ischaemia, the hearts were implanted intra-abdominally, 
anastomosing end-to-side the aorta and pulmonary artery of the 
donor heart with the abdominal aorta and inferior vena cava of the 
recipient, respectively. After completion of the anastomoses, the 
vessels were released and the heart was perfused in situ. 
3.2.2.1. Experimental groups 
The rats were randomly divided into four groups: 1) control, heart 
explanted without any treatment; 2) control + Q50, Q50 
administered 1 h prior to explantation; 3) I/R, donor rats received 
vehicle 1 h prior to explantation, hearts were then subjected to 1 h 
ischaemia and transplanted; 4) Q50 + I/R, Q50 treatment of the 
donor animals 1 h prior to explantation, hearts were then subjected to 
1 h ischaemia and transplanted. Vehicle or Q50 were intravenously 
given.  
3.2.2.2. Haemodynamic measurements 
After 1 h of reperfusion, rats were intraperitoneally anesthetised with 
a mixture of ketamine and xylazine. A balloon catheter was 
introduced into the left ventricle via the apex to determine LV 
function using a Millar micromanometer at different LV volumes. 
LV pressure-volume relationships were constructed using these data. 
At the end of the experiment hearts were removed for further 
analysis. 
3.2.2.3. Determination of high-energy phosphate levels 
Heart tissue was homogenised and using enzyme kinetic assay ATP, 
ADP and AMP contents were expressed as micromoles per gram of 
dry weight.  The energy charge potential was calculated as [ATP + 
0.5 (ADP)]/[ATP + ADP + AMP]. 
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3.2.2.4. Quantitative real-time PCR and Western blotting 
The mRNA and protein expression of cytochrome-c oxidase, SOD-1 
and MMP-2 (data not shown) was determined. Sample 
quantifications were normalised to the GAPDH expression.  
3.2.3. In vitro cardiac myocyte protection studies 
H9c2 rat embryonic cardiac muscle cells were cultured in 
Dulbecco’s Modified Eagle’s Medium and treated with and without 
Q50 30 min after exposure to H2O2. On the following day, H9c2 rat 
embryonic cardiac muscle cells were post-treated (30 min after H2O2 
treatment) with Q50 or a solvent of the compound. The absolute 
control group did not receive the H2O2 treatment. The H2O2 
concentration used here to elicit cell injury (100 µmol/L) was 
previously optimised for H9c2 cells according to their sensitivity to 
oxidative stress. Cells were dynamically monitored over 24 h by 
measuring the electrical impedance every 5 min with real-time cell 
electronic sensing assay.  
3.2.4. Statistical analyses 
All data are expressed as mean ± SEM. For the heart transplantation 
haemodynamic parameters, Student’s t-test was used to analyse 
differences between the groups. In all other cases, means were 
compared between groups by one-way ANOVA with Bonferroni 
correction for multiple post hoc comparisons. P < 0.05 was 
considered statistically significant. 
  
4. RESULTS 
4.1. Effects of prolyl-hydroxylase inhibition on vascular 
function 
4.1.1. Endothelium-dependent vasorelaxation of aortic rings 
In NaOCl group, endothelial dysfunction was indicated by reduced 
Rmax to acethylcholine and right shift of concentration response 
curves of aortic segments to acethylcholine compared with the 
control group. Treatment with DMOG significantly improved 
acethylcholine-induced vasorelaxation. Contractile responses to high 
K
+
-induced depolarization was significantly reduced at high 
concentrations of DMOG compared with those in the control group.  
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Table 1. Contractile responses and vasorelaxation ability in the three groups. 
Values of maximal relaxation (Rmax) and pD2 to acethylcholine and sodium 
nitroprusside in the control, NaOCl-exposed and DMOG-treated aortic rings. Values 
represent mean ± SEM. Significance (P < 0.05): # vs. control; * vs. NaOCl. 
 
4.1.2. Effects of DMOG on relative haem-oxygenase-1 mRNA-
expression 
At the beginning of the warm reperfusion, expression of HO-1 in the 
NaOCl group was significantly reduced compared with that in the 
control. From the second hour of ‘reperfusion’, the aortic segments 
treated with the prolyl-hydroxylase inhibitor showed a significantly 
increased level of an inducible HO form compared with the NaOCl 
treated aortic rings.  
VSMC after 24 h cold storage followed by 6 h warm reperfusion 
relative mRNA-expression of HO-1 was significantly higher in the 
DMOG group than in the NaCl group (data not shown). 
 Control NaOCl DMOG 10−4 M 
Rmax to ACh (%) 95 ± 1 44 ± 4 
# 68 ± 5 #,* 
pD2 to ACh 7.23 ± 0.1 6.46 ± 0.11 6.20 ± 0.44 # 
Rmax to SNP (%) 101 ± 1 101 ± 1 100 ± 1 
pD2 to SNP 8.26 ± 0.06 8.11 ± 0.06 8.33 ± 0.10 
KCl (g) 3.83 ± 0.15 2.52 ± 0.20# 2.74 ± 0.20# 
Phenylephrine (g) 3.25 ± 0.15 3.45 ± 0.15 3.10 ± 0.16 
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Figure 1. HO-1 mRNA-expression. Relative expression of HO-1 in aortic 
segments compared with the expression of GAPDH after 24 h of cold ischaemic 
storage followed by 0, 2, 4 and 6 h of warm reperfusion in the control, NaOCl and 
DMOG groups. After the second hour, the DMOG treated group had significantly 
higher HO-1 mRNA levels. Values represent mean ± SEM. 
4.2. Effect of Q50 treatment on regional and global 
myocardial I/R injury 
Rats subjected to LAD occlusion and reperfusion showed no 
observed difference in the area at risk between the vehicle and Q50 
treated rats, indicating that a comparable degree of ischaemia was 
induced in both groups. Post-ischaemic treatment with Q50 did not 
reduce the myocardial infarct size compared with that in the I/R 
group. 
4.2.1. Effect of Q50 on cardiac function after myocardial 
infarction 
Cardiac parameters of myocardial infarcted rats showed no 
significant difference in heart rate, LV end-diastolic pressure, stroke 
volume, cardiac output, stroke work or slope of EDPVR values in the 
groups compared with those of the controls. However, increased end-
systolic and end-diastolic volumes in myocardial infarcted rats were 
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significantly reduced after post-ischaemic treatment with Q50. In the 
I/R group, decreased LV load-dependent (dP/dtmax) and decreased 
load-independent (slope of dP/dtmax/end-diastolic volume 
relationship and maximum time-varying elastance) contractility 
parameters were significantly increased after post-ischaemic 
treatment with Q50. Moreover, the ejection fraction was significantly 
increased in the I/R + Q50 group compared with that in the I/R 
group. Systolic and diastolic blood pressures and mean arterial 
pressure were significantly reduced in I/R, I/R + Q50 and sham + 
Q50 groups compared with those in the sham operated rats. When 
compared with the sham group, rats with myocardial infarction 
showed significantly decreased LV end-systolic pressure, PRSW, 
dP/dtmin and impaired cardiac relaxation, as reflected by a prolonged 
Tau. Post-ischaemic treatment with Q50 did not significantly restore 
these parameters.  
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Table 2. Cardiac functions in the four groups. LV: left-ventricular; PRSW: 
preload recruitable stroke work; dP/dtmin: maximal slope of the diastolic pressure 
decrement, Tau: time constant of left-ventricular pressure decay; EDPVR: end-
diastolic pressure-volume relationship. *P<0.05 vs. sham, #P<0.05 vs. I/R. 
 
 Parameters Sham Sham+Q50 I/R I/R+Q50 
Basic hemodynamic data 
Heart rate [beats/min] 404±8 431±19 383±17 410±21 
Systolic blood 
pressure [mmHg] 
157±3 139±4* # 116±3* 129±7* 
Diastolic blood 
pressure [mmHg] 
126±3 109±3* # 93±4* 102±5* 
Mean arterial pressure 
[mmHg] 
136±3 119±3* # 101±3* 111±6* 
LV pressures and volumes 
LV end-systolic 
pressure [mmHg] 
136±8 127±5# 110±3* 118±8 
LV end-diastolic 
pressure [mmHg] 
15±2 14±3 16±2 15±4 
End-systolic volume 
[µl] 
52±10 64±20 93±8* 43±8# 
End-diastolic volume 
[µl] 
113±17 120±19# 177±15* 97±13# 
Stroke volume [µl] 61±24 85±7 84±10 86±9 
Ejection phase and pressure-volume relationship indexes 
Ejection fraction [%] 46±15  51 ± 8 47 ± 3 52 ± 10# 
Cardiac output 
[ml/min] 
46±6 38 ± 4 50 ± 9 35 ± 3 
Stroke work 
[mmHg.µl] 
10129±1895 8373 ± 1838 11790 ± 
2031 
6762 ± 1623 
PRSW [mmHg] 93±14 114 ± 12# 75 ± 4* 93 ± 11 
Indexes of the active phase of relaxation 
-dP/dtmin [mmHg/s] 12625±1678 11910±1119
# 7217±275* 8653±967 
Tau [ms] 10.4±0.9 10.4±1.1# 14.6±0.7* 13.9±1.1* 
Index of the passive phase of relaxation 
Slope of  EDPVR 
 [mmHg/µl] 
0.043±0.011 0.070±0.007 0.062±0.011 0.050±0.008 
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4.2.2. Effect of Q50 after heart transplantation 
4.2.2.1. Effect of Q50 on graft function after heart 
transplantation 
At 1 h of reperfusion, LV systolic pressure and dP/dtmax significantly 
increased in the Q50 treated group compared with those in the I/R 
group, indicating improved myocardial contractility. Moreover, Q50 
treatment resulted in a significant increase in dP/dtmin values 
compared with the I/R group, reflecting improved myocardial 
relaxation. LV end-diastolic pressure, as a marker of the standardised 
balloon catheter measurements, did not show major differences. 
 
Table 3. Effects of Q50 on graft function after heart transplantation. Left-
ventricular (LV) parameters 1 h after reperfusion. Q50 treatment resulted in a 
significant increase in LVSP, dP/dtmin and dP/dtmax values compared with the I/R 
group. Values represent the mean ± SEM, P < 0.05: * vs. I/R. 
 
Parameter I/R Q50 + I/R 
LVSP [mmHg] 80 ± 2 105 ± 5* 
dP/dtmax [mmHg/s] 1781 ± 94 3219 ± 190* 
LVEDP [mmHg] 5.5 ± 2.0 7.1 ± 4.1 
dP/dtmin [mmHg/s] 989 ± 115 2477 ± 424* 
 
4.2.2.2. Effect of Q50 on graft myocardial high-energy phosphate 
contents after heart transplantation 
After heart transplantation, myocardial high-energy phosphate 
contents, ATP and ADP levels, were preserved by Q50 pre-
conditioning compared with the I/R group. The energy charge 
potential as an indicator of the myocardial energy level showed a 
significant improvement in Q50 pre-treated rats compared with that 
in the I/R group.  
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Table 4. Effect of Q50 on myocardial ATP, ADP and AMP contents in a rat 
model of heart transplantation. I/R: ischaemia/reperfusion, ATP: adenosine 
triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate. *P < 
0.05 vs. other groups. 
Parameter Control I/R Q50 + I/R 
ATP [µmol/g] 6.58 ± 1.12 1.86 ± 0.41* 6.66 ± 0.63 
ADP [µmol/g] 3.48 ± 0.16 2.05 ± 0.42* 5.01 ± 0.43 
AMP [µmol/g] 1.91 ± 0.22 2.07 ± 0.22 2.59 ± 0.61 
Energy charge potential 0.69 ± 0.07 0.49 ± 0.04* 0.85 ± 0.08 
4.2.2.3. Effect of Q50 on graft gene and protein expression after 
heart transplantation 
Quantitative real-time PCR from myocardium RNA extracts revealed 
that relative mRNA expression for SOD-1 and cytochrome-c oxidase 
remained unchanged in control, control Q50 and I/R groups. 
However, their expressions were significantly upregulated after a 
Q50 treatment compared with that in the control group. Furthermore, 
densitometric analysis of bands after heart transplantation showed 
that a Q50 treatment significantly upregulated the protein expression 
of SOD-1 compared with the control and I/R groups and increased 
cytochrome-c oxidase protein level compared with the controls (data 
not shown). 
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Figure 2. Effects of Q50 on gene expression after heterotopic heart 
transplantation. (A) SOD-1, (B) cytochrome-c oxidase mRNA expression in the 
myocardium. SOD-1 and cytochrome-c oxidase were significantly up-regulated in 
the Q50 pre-treated I/R group compared with those in the control group. Values 
represent mean ± SEM, P < 0.05: * vs. control. 
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4.2.3. Cytoprotective effect of Q50 post-treatment of H9c2 cells  
Cells were attached and grown overnight; they were then subjected 
to H2O2 induced oxidative stress. After 30 min, Q50 was added to the 
wells at given concentrations. Normalisation of the cell index was 
calculated at the time of H2O2 application. Exposure of H9c2 cells to 
100 μM H2O2 resulted in a rapid decrease of the cell index, whereas 
the cell index of the absolute control cells that did not receive H2O2 
treatment continued to slightly increase. Post-treatment of Q50 
exerted a dramatic dose-dependent cytoprotective effect after H2O2 
stress: concentrations as low as 0.5 μM maintained the cell index 
near absolute control levels after the initial 3 h of the experiments. 
The cell index also remained markedly elevated during the course of 
the entire experiment. 
 
 
Figure 3. Cytoprotective effect of the Q50 post-treatment of H9c2 cells after 
oxidative stress. H9c2 rat embryonal cardiac muscle cells were subjected to 
oxidative stress (100 μM H2O2; arrow 1). After 30 min, Q50 was added to the wells 
(arrow 2). Curves in the figure are measurements of single wells. The normalised 
cell index shows the relative viability of cells per well. The black vertical line in the 
middle of the graph indicates the time of normalisation of the cell index, which is 
the time of H2O2 application. 
Time (hours) 
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5. CONCLUSIONS 
Exploring research areas of experimental cardiology and heart 
surgery for better understanding of myocardial and vessel protection 
under ischaemic and hypoxic conditions is necessary to improve our 
knowledge regarding the circumstances of these conditions.  
 
The first aim of this study focused on the role of the HIF in vascular 
cold ischaemic storage and warm reperfusion injury. Therefore, we 
treated isolated rat aortic rings with DMOG and simulated 
reperfusion injury in an organ bath by adding hypochlorite. We 
found that HIF stabilisation leads to an improvement in 
vasorelaxation, which was mainly mediated via HO-1. 
 
Our second aim was to investigate the activity and characteristics of 
the newly developed iron-chelating and zinc-complexing agent Q50 
in rodent models of regional and global myocardial I/R. In rats with 
regional myocardial ischaemia induced by ligation of the LAD 
coronary artery, we found that treatment with Q50 showed improved 
contractility, although the size of myocardial infarct was not 
influenced. Rats with global myocardial ischaemia from an 
orthotopic heart transplantation that were treated with Q50 showed 
better LV function and increased ATP levels compared with those in 
the control groups. 
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